Eli Lilly`s Rayvow (lasmiditan) Receives Approval in Europe
Eli Lilly Japan and Daiichi Sankyo Company have concluded an agreement on commercialization collaboration in Japan for the 5-HT1F receptor agonist lasmiditan succinate, for which Eli Lilly Japan has submitted a new drug application for the treatment of migraines.
INDIANAPOLIS, Oct. 6, 2020 /PRNewswire/ -- Adults who took REYVOW® (lasmiditan) C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 7.2 times greater odds, respectively, of achieving superior pain freedom at 2 hours post treatment compared to those taking placebo in at least 2 out of 3 attacks (co-primary endpoint), new findings from the recently completed Phase 3 study CENTURION reveal. This co-primary endpoint result translated to therapeutic gains, or differences between REYVOW and placebo groups, of approximately 10-20%. Moreover, in at least 2 out of 3 attacks, Eli Lilly and Company's (NYSE: LLY) REYVOW demonstrated superiority over placebo in pain relief at 2 hours. In addition, significantly more study participants who treated their migraine attacks with REYVOW achieved pain freedom and pain relief at 2 hours in 2 out of 3 attacks with REYVOW versus those on placebo, even if they had previously tried triptans that were ineffective, intolerable or became contraindicated. As previously reported, REYVOW demonstrated superiority over placebo in all of the study's 18 gated endpoints. Study investigator Dr. Messoud Ashina, M.D., professor of neurology, Danish Headache Center and Dept. of Neurology, University of Copenhagen, Copenhagen, Denmark and Dr. Uwe Reuter, M.D., Ph.D., professor of neurology, Charite University Hospital of Berlin, Berlin, Germany, are presenting these results and answering questions virtually at the 18th Migraine Trust International Symposium (MTIS 2020), during a session on Oct. 7th, 4:45 – 5:45 p.m. CEDT/10:45 – 11:45 a.m. EDT.
With several new acute migraine treatments vying for market share, Eli Lilly is touting new data on Reyvow showing the med can provide patients “pain freedom” in as little as one hour, plus sustained relief for up to two days.
Eli Lilly (NYSE:LLY) announces positive results from a 1,471-subject Phase 3 clinical trial, CENTURION, evaluating 100 mg and 200 mg doses of Reyvow (lasmiditan) for the acute treatment of migraine in adults, with or without aura, across four attacks. The data are being presented virtually at PAINWeek.
ICER comes around on Allergan, Biohaven migraine meds
(Reuters) - Eli Lilly and Co (LLY.N) on Friday priced its acute migraine treatment at $640 for a pack of eight pills and said it will be made available in pharmacies in the next few days.
Eli Lilly's Emgality has been gaining steam in the new CGRP class of migraine prevention drugs, and now it has a new colleague: Reyvow, the first med in a new class of acute treatments.
Eli Lilly and Company (NYSE: LLY) announced today that REYVOW™ (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults, is now available for prescription and will be available in pharmacies in the next few days.1 REYVOW works differently than other acute treatments for migraine. REYVOW is a new class of acute treatment for migraine, as it is the first and only FDA-approved ditan, a 5-HT1F receptor agonist, believed to act both centrally and peripherally.1 REYVOW is available in 50 mg, 100 mg and 200 mg doses for patients, which offers dosing flexibility for physicians and other prescribers.